Status:
ACTIVE_NOT_RECRUITING
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Lead Sponsor:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18-95 years
Brief Summary
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
Detailed Description
Blood samples will be tested by Natera to identify residual tumor DNA for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.
Eligibility Criteria
Inclusion
- Clinical diagnosis of epithelial ovarian cancer stage II-IV
Exclusion
- Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial
Key Trial Info
Start Date :
October 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05212779
Start Date
October 7 2022
End Date
December 30 2024
Last Update
February 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AHN West Penn Hospital
Pittsburgh, Pennsylvania, United States, 15224